Interpace Beneish M Score

IDXG
 Stock
  

USD 1.65  0.15  10.00%   

This module uses fundamental data of Interpace Diag to approximate the value of its Beneish M Score. Interpace Diag M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Please see Interpace Diag Piotroski F Score and Interpace Diag Altman Z Score analysis.
  
Interpace Diag Long Term Debt to Equity is projected to slightly decrease based on the last few years of reporting. The past year's Long Term Debt to Equity was at 0.09. The current year Debt to Equity Ratio is expected to grow to 0.09, whereas Debt Current is forecasted to decline to about 1 M. Interpace Diag PPandE Turnover is projected to decrease significantly based on the last few years of reporting. The past year's PPandE Turnover was at 7.24. The current year Receivables Turnover is expected to grow to 2.88, whereas Return on Investment is forecasted to decline to (87.27) .
At this time, it appears that Interpace Diag Group is an unlikely manipulator. The earnings manipulation may begin if Interpace Diag's top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Interpace Diag executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Interpace Diag's earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-3.02
Beneish M Score - Unlikely Manipulator
Elasticity of Receivables1.0Focus
Asset Quality1.03Focus
Expense Coverage0.91Focus
Gross Margin Strengs0.96Focus
Accruals Factor0.91Focus
Depreciation Resistance1.1Focus
Net Sales Growth1.03Focus
Financial Leverage Condition1.06Focus

Interpace Diag Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Interpace Diag's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Selling General and Administrative Expense22.2 M23.7 M
Notably Down
Decreasing
Slightly volatile
Revenues28.4 M27.7 M
Fairly Up
Decreasing
Slightly volatile
Trade and Non Trade Receivables6.3 M6.2 M
Fairly Up
Decreasing
Slightly volatile
Property Plant and Equipment Net11.2 M10.4 M
Significantly Up
Increasing
Slightly volatile
Net Cash Flow from Operations(22.4 M)(21.8 M)
Fairly Down
Decreasing
Slightly volatile
Liabilities Non Current16.9 M18.6 M
Moderately Down
Increasing
Very volatile
Current Liabilities25.8 M19.9 M
Significantly Up
Decreasing
Slightly volatile
Total Liabilities43.1 M34.3 M
Significantly Up
Decreasing
Slightly volatile
Investments Current95.3 K95.4 K
Slightly Down
Decreasing
Slightly volatile
Investments95.3 K95.4 K
Slightly Down
Decreasing
Slightly volatile
Gross Margin29.2930.62
Sufficiently Down
Increasing
Slightly volatile
Depreciation Amortization and AccretionM5.4 M
Significantly Down
Increasing
Slightly volatile
Debt Non Current11.1 M12.6 M
Fairly Down
Decreasing
Slightly volatile
Debt CurrentMM
Slightly Down
Decreasing
Slightly volatile
Total Debt11.2 M12.6 M
Fairly Down
Decreasing
Slightly volatile
Assets Non Current31.9 M26.3 M
Fairly Up
Increasing
Very volatile
Current Assets19.3 M18.8 M
Fairly Up
Decreasing
Slightly volatile
Total Assets87.1 M79.4 M
Significantly Up
Decreasing
Slightly volatile

Interpace Diag Group Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Interpace Diag's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Interpace Diag in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Interpace Diag's degree of accounting gimmicks and manipulations.

About Interpace Diag Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Depreciation Amortization and Accretion

5 Million

Interpace Diag Depreciation Amortization and Accretion is projected to increase significantly based on the last few years of reporting. The past year's Depreciation Amortization and Accretion was at 5.37 Million

Interpace Diag Earnings Manipulation Drivers

Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as Interpace Diag. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
201720182019202020212022 (projected)
Revenues13.09 M15.9 M21.9 M24.08 M27.69 M28.42 M
Total Assets41.78 M53.6 M48.44 M69.05 M79.41 M87.05 M
Current Assets4.24 M19.81 M17.72 M16.37 M18.82 M19.32 M
Assets Non Current33.79 M13.41 M35.03 M31.56 M26.26 M31.9 M
Total Liabilities35.25 M13.73 M15.5 M29.85 M34.33 M43.13 M
Current Liabilities16.24 M8.09 M8.49 M17.3 M19.89 M25.77 M
Total Debt8.4 M7.91 M5.59 M3.54 M12.6 M11.2 M
Debt Non Current7.23 M7.91 M5.59 M3.54 M12.6 M11.12 M
Operating Income(6.44 M)(6.29 M)(12.12 M)(26.42 M)(30.39 M)(32.79 M)
Gross Margin49.2553.7153.4334.0230.6229.29

About Interpace Diag Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Interpace Diag Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Interpace Diag using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Interpace Diag Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey. Interpace Diag operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 147 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Interpace Diag in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Interpace Diag's short interest history, or implied volatility extrapolated from Interpace Diag options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Interpace Diag Group using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Interpace Diag Piotroski F Score and Interpace Diag Altman Z Score analysis. You can also try Price Transformation module to use Price Transformation models to analyze depth of different equity instruments across global markets.

Complementary Tools for analysis

When running Interpace Diag Group price analysis, check to measure Interpace Diag's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Interpace Diag is operating at the current time. Most of Interpace Diag's value examination focuses on studying past and present price action to predict the probability of Interpace Diag's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Interpace Diag's price. Additionally, you may evaluate how the addition of Interpace Diag to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Please note, there is a significant difference between Interpace Diag's value and its price as these two are different measures arrived at by different means. Investors typically determine Interpace Diag value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Interpace Diag's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.